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Background:
African American (AA) and Hispanic patients suffer disproportionately from severe asthma,
however are often under-represented within clinical trials of asthma therapies. Monoclonal
antibody therapies are shown to be effective in trials to treat patients with severe asthma
phenotype.
Objectives/Goal:
We aimed to describe the racial/ethnic makeup of FDA approved biological therapies for asthma.
Methods/Design:
We identified clinical trials in ClinicalTrials.gov of Omalizumab, Mepolizumab, and Reslizumab that
assessed safety/efficacy for asthma. The search strategy included the terms “asthma,” drug name,
and “United States” . We determined frequency (%) of studies where study participant
racial/ethnic demographics were reported; and among these studies the % of racial/ethnic
minority inclusion.
Results:

Among the n= 29 studies, racial/ethnic demographics were reported in ClinicalTrials.gov for 25%
(3 out of 12 studies), 100% (11 out of 11 studies), 83% (5 out of 6 studies) for Omalizumab,
Mepolizumab, and Reslizumab respectively. For Omalizumab, mean% (SD) of racial demographics
for study participants were: 40.2% (32.8) AA, 41% (40) Caucasian, 6.65% (14.6) Hispanic.
Mepolizumab study demographic mean% (SD) were: 5.4 % (5.8) were (AA), 83.9 (10.5) were
Caucasian, 0% (0) were Hispanic. Among the Reslizumab studies, mean% (SD) of ethnic/racial
demographics were: 9.22% (10.1) AA, 74% (4.62) Caucasian, 13.5% (37.9) Hispanic.

Conclusions:
Racial/ethnic demographic data are reported for the majority of clinical trials of biological
therapies to treat asthma. However, the racial/ethnic makeup of these trials are often not
representative of the US asthma population. Future trials to establish asthma therapeutic
efficacy/safety should be conducted amongst a representative population.

